Cargando…
What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082295/ https://www.ncbi.nlm.nih.gov/pubmed/32206564 http://dx.doi.org/10.21037/tlcr.2019.12.06 |
| _version_ | 1783508317975347200 |
|---|---|
| author | Bravaccini, Sara Ulivi, Paola |
| author_facet | Bravaccini, Sara Ulivi, Paola |
| author_sort | Bravaccini, Sara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7082295 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70822952020-03-23 What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? Bravaccini, Sara Ulivi, Paola Transl Lung Cancer Res Letter to the Editor AME Publishing Company 2020-02 /pmc/articles/PMC7082295/ /pubmed/32206564 http://dx.doi.org/10.21037/tlcr.2019.12.06 Text en 2020 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Letter to the Editor Bravaccini, Sara Ulivi, Paola What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? |
| title | What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? |
| title_full | What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? |
| title_fullStr | What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? |
| title_full_unstemmed | What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? |
| title_short | What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors? |
| title_sort | what’s the best modality for patient selection for predicting response to pd-1/pd-l1 inhibitors? |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082295/ https://www.ncbi.nlm.nih.gov/pubmed/32206564 http://dx.doi.org/10.21037/tlcr.2019.12.06 |
| work_keys_str_mv | AT bravaccinisara whatsthebestmodalityforpatientselectionforpredictingresponsetopd1pdl1inhibitors AT ulivipaola whatsthebestmodalityforpatientselectionforpredictingresponsetopd1pdl1inhibitors |